Erste Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Erste Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.3M	Sell	221,705 -50,000	-18%	-$356K	0.01%	421
2025 Q4	$1.96M	Buy	271,705 +11,694	+4%	+$94.6K	0.02%	350
2025 Q3	$2.56M	Hold	260,011	–	–	0.02%	325
2025 Q2	$2.7M	Hold	260,011	–	–	0.02%	357
2025 Q1	$3.43M	Buy	260,011 +86,445	+50%	+$1.54M	0.04%	255
2024 Q4	$3.26M	Hold	173,566	–	–	0.04%	278
2024 Q3	$2.8M	Buy	173,566 +51,333	+42%	+$802K	0.03%	282
2024 Q2	$3.31M	Buy	122,233 +15,163	+14%	+$362K	0.04%	266
2024 Q1	$2.09M	Buy	107,070 +2,837	+3%	+$60.1K	0.03%	299
2023 Q4	$2.16M	Buy	104,233 +20,000	+24%	+$597K	0.03%	289
2023 Q3	$2.69M	Buy	84,233 +6,666	+9%	+$223K	0.05%	250
2023 Q2	$2.61M	Buy	77,567 +8,334	+12%	+$298K	0.05%	255
2023 Q1	$2.88M	Hold	69,233	–	–	0.06%	259
2022 Q4	$2.35M	Hold	69,233	–	–	0.05%	266
2022 Q3	$3.4M	Sell	69,233 -16,667	-19%	-$915K	0.08%	238
2022 Q2	$3.37M	Buy	85,900 +18,333	+27%	+$544K	0.07%	245
2022 Q1	$2.5M	Buy	67,567 +27,234	+68%	+$1.7M	0.05%	272
2021 Q4	$4.04M	Buy	+40,333	New	+$4.34M	0.07%	228

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Erste Asset Management's RNAC Position: Q1 2026 in Review

Erste Asset Management reduced its Cartesian Therapeutics (RNAC) stake by 18% in Q1 2026, selling an estimated $356K and leaving 221,705 shares worth $1.3M. The position accounts for 0.01% of the portfolio, ranked #421.

Erste Asset Management first reported a position in RNAC in Q4 2021 and has held it in 18 quarters since. The position peaked at $4.04M in Q4 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Erste Asset Management held 221,705 shares of Cartesian Therapeutics worth $1.3M as of Q1 2026.
Erste Asset Management sold 50,000 Cartesian Therapeutics shares in Q1 2026, an estimated $356K.
Cartesian Therapeutics made up 0.01% of Erste Asset Management's portfolio in Q1 2026, its #421 holding.
Erste Asset Management first reported a position in Cartesian Therapeutics in Q4 2021 and has held it in 18 quarters since.
Erste Asset Management's Cartesian Therapeutics position peaked at $4.04M in Q4 2021.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Erste Asset Management's 13F filing for Q1 2026, filed 11 May 2026.